On November 20, Twist Bioscience Corp fell 8.35% in Pre-Market Trading, trading at $106.27 per share, with turnover of $189,700.
The move came as the market continued to digest the company’s latest quarterly results, management’s indication of slower AI drug discovery-related growth, and several post-earnings target-price cuts that pressured near-term sentiment.
Background context shows Twist Bioscience Corp reported fiscal fourth-quarter revenue of $126.6 million and a loss of $0.32 per share, both better than consensus. Fiscal first-quarter revenue guidance of $130 million to $132 million and full-year revenue guidance of $550 million to $560 million were also slightly above expectations. Even so, UBS cut its target price to $120, Jefferies lowered its target to $125, and Guggenheim reduced its target to $150, while Piper Sandler raised its target to $140, underscoring a split analyst view as investors reassessed the company’s growth outlook.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments